Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the…
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusionSleeping Beauty TCR-T cell therapy had a…